Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments

Ovarian cancer (OC) remains a fatal malignancy because most patients experience recurrent disease, which is resistant to chemotherapy. The outcomes for patients with platinum-resistant OC are poor, response rates to further chemotherapy are low and median survival is lower than 12 months. The comple...

Full description

Saved in:
Bibliographic Details
Published inSeminars in cancer biology Vol. 77; pp. 144 - 166
Main Authors Marchetti, Claudia, De Felice, Francesca, Romito, Alessia, Iacobelli, Valentina, Sassu, Carolina Maria, Corrado, Giacomo, Ricci, Caterina, Scambia, Giovanni, Fagotti, Anna
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.12.2021
Subjects
Animals
Biomarkers, Tumor
Carcinoma, Ovarian Epithelial - drug therapy
Drug Resistance, Neoplasm - drug effects
Female
Humans
Innovative drugs
Ovarian cancer
Platinum resistance
Predictive biomarkers
Platinum resistance
Innovative drugs
Predictive biomarkers
Ovarian cancer
Online AccessGet full text

Cover

More Information
Summary:Ovarian cancer (OC) remains a fatal malignancy because most patients experience recurrent disease, which is resistant to chemotherapy. The outcomes for patients with platinum-resistant OC are poor, response rates to further chemotherapy are low and median survival is lower than 12 months. The complexity of platinum-resistant OC, which comprises a heterogeneous spectrum of diseases, is indeed far from being completely understood. Therefore, comprehending tumors’ biological behaviour to identify reliable biomarkers, which may predict responses to therapies, is a demanding challenge to improve OC management. In the age of precision medicine, efforts to overcome platinum resistance in OC represent a dynamic and vast field in which innovative drugs and clinical trials rapidly develop. This review will present the exceptional biochemical environment implicated in OC and highlights mechanisms of chemoresistance. Furthermore, innovative molecules and new therapeutic opportunities are presented, along with currently available therapies and ongoing clinical trials.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1044-579X
1096-3650
DOI:10.1016/j.semcancer.2021.08.011